AR and cancer: PD-L1 expression was significantly more common in cancers with lymphocytic infiltrates (OR, 3.3; 95% CI 1.1–10.4) and androgen receptor expression (OR, 3.2; 95% CI 1.4–7.5), and less common in tumors with lymphovascular invasion (OR 0.41; 95% CI 0.18–0.92).